Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.96 USD | -1.75% | -7.50% | 0.00% |
04-22 | Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target | MT |
04-22 | Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 203M | |
+14.06% | 118B | |
+12.50% | 106B | |
-4.50% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.34% | 15.56B | |
+4.06% | 13.63B | |
+27.39% | 12.27B |
- Stock Market
- Equities
- BOLD Stock
- News Boundless Bio, Inc.
- Boundless Bio Insider Bought Shares Worth $3,200,000, According to a Recent SEC Filing